Engineering in Precision Medicine

Wednesday, July 7, 2021 | 1:00 p.m. – 2:00 p.m.
Headshot-Dr.-Khademhosseini.jpg

Ali Khademhosseini, PhD, Chief Executive Officer, Terasaki Institute for Biomedical Innovation, is interested in developing ‘personalized’ solutions that utilize micro- and nanoscale technologies to enable a range of therapies for organ failure, cardiovascular disease and cancer. His group also aims to engineer tissue regenerative therapeutics using water-containing polymer networks called hydrogels that can regulate cell behavior. Specifically, he has developed photo-crosslinkable hybrid hydrogels that combine natural biomolecules with nanoparticles to regulate the chemical, biological, mechanical and electrical properties of gels. It is anticipated that such approaches will lead to the development of next-generation regenerative therapeutics and biomedical devices.